Skip to main content
Evidence Snapshot

Tyrosine-protein kinase SYK

CHEMBL2599 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2599
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase SYK as ChEMBL target CHEMBL2599, mapped to UniProt P43405. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase SYK
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2599
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P43405
Tyrosine-protein kinase SYK
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase SYK matters

As of 2026-09-13

Tyrosine-protein kinase SYK is reviewed as Tyrosine-protein kinase SYK (UniProt P43405); Tyrosine-protein kinase SYK shows approved-linked disease relevance led by autoimmune thrombocytopenic purpura. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 21 approved drugs, 7852 compounds, and 863 assays, with lead potency reaching pChEMBL 11.0.

Disease context
autoimmune thrombocytopenic purpura

Tyrosine-protein kinase SYK shows approved-linked disease relevance led by autoimmune thrombocytopenic purpura. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include FOSTAMATINIB, FOSTAMATINIB DISODIUM, SOVLEPLENIB.

Start review with autoimmune thrombocytopenic purpura because it currently carries approved-linked support. Linked drugs include FOSTAMATINIB, FOSTAMATINIB DISODIUM, SOVLEPLENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 3 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 21 approved drugs, 7852 compounds, and 863 assays for this target. The dominant activity type is IC50. CHEMBL3415598 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL3415598 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
21 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase SYK matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P43405, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why autoimmune thrombocytopenic purpura is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

7852
Total Compounds
863
Total Assays
21
Approved Drugs
IC50: 7635.0, KI: 613.0, EC50: 262.0, KD: 416.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3415598
 11.0 IC50 —
No preferred name
CHEMBL4744190
 10.5 IC50 —
No preferred name
CHEMBL3622956
 10.5 IC50 —
No preferred name
CHEMBL5425739
 10.3 IC50 —
No preferred name
CHEMBL4780257
 10.2 IC50 —

Approved Drugs

Structure Compound First Approval
ENTRECTINIB
CHEMBL1983268
 2019
FOSTAMATINIB
CHEMBL2103830
 2018
FOSTAMATINIB DISODIUM
CHEMBL3989516
 2018
MIDOSTAURIN
CHEMBL608533
 2017
BOSUTINIB
CHEMBL288441
 2012
DASATINIB
CHEMBL5416410
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2599